Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

FOXO4-DRI_15MG

FOXO4-DRI

FOXO4-DRI is a synthetic peptide designed as a D-retro-inverso (DRI) analog of a region derived from the Forkhead box O4 (FOXO4) protein. In laboratory research, FOXO4-DRI has been utilized as a molecular research tool to study protein–protein interactions, transcription factor signaling, and cellular regulatory mechanisms associated with FOXO family pathways.*

The D-retro-inverso design confers enhanced resistance to proteolytic degradation in experimental systems, making FOXO4-DRI suitable for controlled in vitro and preclinical research models where peptide stability is a critical variable.*

  • Peptide Name: FOXO4-DRI
  • Peptide Class: Synthetic D-retro-inverso peptide
  • Design: D-amino acid, retro-inverso configuration
  • Form: Lyophilized powder
  • Purity: ≥99% (HPLC verified)
  • Quantity: 10 mg per vial
  • Analytical Verification: HPLC and Mass Spectrometry (MS)
  • Manufacturing: Synthesized and quality-tested under controlled laboratory conditions
  • Designation: For Research Use Only (RUO)

$300.00

$285.00 each
$270.00 each

Products will arrive in a lyophilized (powder) form for maximum stability.

Free domestic shipping on orders over $300

FOXO4-DRI

Scientific & Research Context

FOXO transcription factors are widely studied in molecular biology for their roles in cellular stress responses, transcriptional regulation, and protein signaling networks.* FOXO4-DRI has been examined in published research as a tool compound for probing FOXO4-associated protein interactions and downstream signaling behavior in experimental systems.*

Within research environments, FOXO4-DRI has been used to investigate:*

  • FOXO protein interaction dynamics and signaling pathways*
  • Transcription factor–mediated regulatory mechanisms*
  • Cellular stress and senescence-associated signaling models*
  • Structure–function relationships of D-retro-inverso peptides*
  • Stability and intracellular behavior of protease-resistant peptides*

Its retro-inverso configuration allows researchers to evaluate how peptide orientation and chirality influence biological interactions in controlled laboratory settings.*

Quality & Analytical Assurance

Each batch of FOXO4-DRI undergoes comprehensive analytical testing to confirm molecular identity, sequence integrity, and purity using validated HPLC and MS methodologies. These quality controls ensure consistency, reliability, and reproducibility across research applications.

Storage & Handling

FOXO4-DRI is supplied in lyophilized form to enhance stability during storage and transport. Store unopened vials in a cool, dry environment protected from light. Reconstitution and handling should follow established peptide research and laboratory best practices to preserve molecular integrity.

For further information on proper storage techniques, click the button…

Storage Instructions

Referenced Scientific Literature
Provided for informational and educational purposes only

  • Baar MP, Brandt RMC, Putavet DA, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell, 2017; 169(1): 132–147.e16.
  • Baar MP, et al. Disruption of FOXO4–p53 interaction using a D-retro-inverso peptide induces apoptosis in senescent cells. Nature Communications, 2017; 8: 16001.
  • Krimpenfort P, Berns A. Rejuvenation by therapeutic elimination of senescent cells. Cell, 2017; 169(1): 3–5.
  • Martins R, Lithgow GJ, Link W. Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. Aging Cell, 2016; 15(2): 196–207.
  • Eijkelenboom A, Burgering BMT. FOXOs: signaling integrators for homeostasis maintenance. Nature Reviews Molecular Cell Biology, 2013; 14(2): 83–97.
  • Calnan DR, Brunet A. The FoxO code. Oncogene, 2008; 27(16): 2276–2288.
  • Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene, 2005; 24(50): 7410–7425.
  • Chen AT-Y, et al. Longevity genes revealed by integrative analysis of isoform-specific daf-16/FoxO mutants of Caenorhabditis elegans. Genetics, 2015; 201(2): 613–629.
  • Murtaza G, Khan AK, Rashid R, Muneer S, Hasan SMF, Chen J. FOXO transcriptional factors and long-term living. Oxidative Medicine and Cellular Longevity, 2017; 2017.
  • Lee S, Dong HH. FoxO integration of insulin signaling with glucose and lipid metabolism. Journal of Endocrinology, 2017; 233(2): R67–R79.
  • Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell, 2008; 133(3): 403–414.
  • Zhou M, et al. Structural basis for FOXO4 interaction with p53 and regulation of senescence-associated transcriptional programs. Journal of Molecular Biology, 2018; 430(24): 4919–4934.
  • Liu W, Song Y, Wang J, Xiao H, Zhang Y, Luo B. Dysregulation of FOXO transcription factors in Epstein–Barr virus-associated gastric carcinoma. Virus Research, 2019; 197808.
  • Hu W, et al. Roles of forkhead box O (FoxO) transcription factors in neurodegenerative diseases: a panoramic view. Progress in Neurobiology, 2019; 181: 101645.
  • Bulteau A-L, Szweda LI, Friguet B. Age-dependent declines in proteasome activity in the heart. Archives of Biochemistry and Biophysics, 2002; 397(2): 298–304.
  • Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron, 2003; 40(2): 427–446.
  • Fischer PM. D-peptides as inhibitors of protein–protein interactions. Current Opinion in Chemical Biology, 2003; 7(4): 456–462.
  • Fontaine F, et al. D-retro-inverso peptides as stable mimetics of bioactive peptides: design principles and biological applications. Current Pharmaceutical Design, 2008; 14(24): 2438–2449.
  • Senescence and aging: causes, consequences, and therapeutic avenues. Journal of Cell Biology, 2018; 217(1): 65–77.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.